BR112017022691A2 - inibidor de bromodomínio. - Google Patents

inibidor de bromodomínio.

Info

Publication number
BR112017022691A2
BR112017022691A2 BR112017022691-0A BR112017022691A BR112017022691A2 BR 112017022691 A2 BR112017022691 A2 BR 112017022691A2 BR 112017022691 A BR112017022691 A BR 112017022691A BR 112017022691 A2 BR112017022691 A2 BR 112017022691A2
Authority
BR
Brazil
Prior art keywords
bromodomain inhibitor
bromodomain
inhibitor
Prior art date
Application number
BR112017022691-0A
Other languages
English (en)
Inventor
Manuel Betancort Juan
Alan Stafford Jeffrey
STANSFIELD Ryan
Marvin Veal James
Original Assignee
Celgene Quanticel Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research, Inc. filed Critical Celgene Quanticel Research, Inc.
Publication of BR112017022691A2 publication Critical patent/BR112017022691A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112017022691-0A 2015-04-22 2016-04-22 inibidor de bromodomínio. BR112017022691A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562151205P 2015-04-22 2015-04-22
US62/151,205 2015-04-22
PCT/US2016/029029 WO2016172618A1 (en) 2015-04-22 2016-04-22 Bromodomain inhibitor

Publications (1)

Publication Number Publication Date
BR112017022691A2 true BR112017022691A2 (pt) 2018-07-17

Family

ID=57143581

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017022691-0A BR112017022691A2 (pt) 2015-04-22 2016-04-22 inibidor de bromodomínio.

Country Status (23)

Country Link
US (1) US20160310423A1 (pt)
EP (1) EP3285770A4 (pt)
JP (1) JP2018513863A (pt)
KR (1) KR20170139119A (pt)
CN (1) CN107613981A (pt)
AR (1) AR104340A1 (pt)
AU (1) AU2016252992A1 (pt)
BR (1) BR112017022691A2 (pt)
CA (1) CA2983446C (pt)
CL (1) CL2017002679A1 (pt)
CO (1) CO2017011482A2 (pt)
EA (1) EA201792317A1 (pt)
EC (1) ECSP17071545A (pt)
HK (1) HK1243948A1 (pt)
IL (1) IL255120B (pt)
MX (2) MX2020010899A (pt)
NZ (1) NZ736630A (pt)
PE (1) PE20180036A1 (pt)
PH (1) PH12017501933A1 (pt)
SG (1) SG11201708627TA (pt)
TW (1) TW201642860A (pt)
WO (1) WO2016172618A1 (pt)
ZA (1) ZA201707186B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
US10702517B2 (en) 2015-04-22 2020-07-07 Celgene Quanticel Research, Inc. Bromodomain inhibitor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2018075796A1 (en) * 2016-10-20 2018-04-26 Celgene Quanticel Research, Inc Bromodomain inhibitor
DK3532059T3 (da) 2016-10-27 2022-03-14 Celgene Quanticel Res Inc Kombinationsterapi med bromdomæne- og ekstraterminal proteinhæmmer
EP3826992A2 (en) * 2018-07-23 2021-06-02 Celgene Quanticel Research, Inc. Process for the preparation of bromodomain inhibitor
CN117136057A (zh) * 2021-02-22 2023-11-28 赛尔基因昆蒂赛尔研究公司 用于治疗***癌的溴结构域(bet)抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
FI3640241T3 (fi) * 2013-10-18 2023-01-13 Bromodomeeni-inhibiittorit
WO2018075796A1 (en) * 2016-10-20 2018-04-26 Celgene Quanticel Research, Inc Bromodomain inhibitor

Also Published As

Publication number Publication date
PH12017501933A1 (en) 2018-03-19
EP3285770A4 (en) 2018-10-31
ECSP17071545A (es) 2017-12-01
US20160310423A1 (en) 2016-10-27
AU2016252992A1 (en) 2017-11-09
CA2983446A1 (en) 2016-10-27
CO2017011482A2 (es) 2018-01-31
MX2017013501A (es) 2018-02-09
CN107613981A (zh) 2018-01-19
JP2018513863A (ja) 2018-05-31
EP3285770A1 (en) 2018-02-28
CA2983446C (en) 2024-04-09
IL255120B (en) 2021-03-25
ZA201707186B (en) 2019-01-30
WO2016172618A1 (en) 2016-10-27
IL255120A0 (en) 2017-12-31
MX2020010899A (es) 2022-02-15
SG11201708627TA (en) 2017-11-29
TW201642860A (zh) 2016-12-16
PE20180036A1 (es) 2018-01-09
CL2017002679A1 (es) 2018-05-25
KR20170139119A (ko) 2017-12-18
HK1243948A1 (zh) 2018-07-27
AR104340A1 (es) 2017-07-12
EA201792317A1 (ru) 2018-03-30
NZ736630A (en) 2024-03-22

Similar Documents

Publication Publication Date Title
FIC20230006I1 (fi) Vutrisiraani
DK3627029T3 (da) Manipulationssikret låg
DK3283625T3 (da) Nukleasemedieret genomeditering
MA52814A (fr) Inhibiteurs de bromodomaine
DK3331869T3 (da) Muscarinagonister
DK3305788T3 (da) Janus-kinase-hæmmer
FR3039337B1 (fr) Motoreducteur compact
DK3277719T3 (da) Polypeptider
DK3360890T3 (da) Genterapi
DK3331528T3 (da) Muskarinagonister
DK3253762T3 (da) 9h-pyrrolo-dipyridinderivater.
DK3310450T3 (da) Olie-vand-separator
DK3331529T3 (da) Muskarinagonister
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
BR112017022691A2 (pt) inibidor de bromodomínio.
DK3270930T3 (da) Præeklampsi
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
KR20180084876A (ko) 내플라즈마성 부재
DK3394281T3 (da) Gærcelle
DK3292136T3 (da) Penicillin-g-acylaser
IT201600084952A1 (it) Coglifrutta.
ES1150114Y (es) Abarcón.
DE112015006486A5 (de) Inkubationsrinne
DK3318308T3 (da) Badmintonketsjer
DK3274482T3 (da) Stenborsknop

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]